Abemaciclib

Generic Name
Abemaciclib
Brand Names
Verzenio, Verzenios
Drug Type
Small Molecule
Chemical Formula
C27H32F2N8
CAS Number
1231929-97-7
Unique Ingredient Identifier
60UAB198HK
Background

Abemaciclib is an antitumor agent and dual inhibitor of cyclin-dependent kinases 4 (CDK4) and 6 (CDK6) that are involved in the cell cycle and promotion of cancer cell growth in case of unregulated activity. On September 28, 2017, FDA granted approval of abemaciclib treatment under the market name Verzenio for the treatment of HR-positive and HER2-negative a...

Indication

适应症为:⑴单药治疗接受过内分泌疗法和化疗后疾病进展的 ER+/HER2-晚期或转移性乳腺癌；⑵或联合氟维司群，二线治疗接受过内分泌疗法后疾病进展的 ER+/HER2-晚期或转移性乳腺癌；⑶联合芳香酶抑制剂作为 ER+/HER2-绝经后女性晚期或转移性乳腺癌的初始内分泌疗法。

Associated Conditions
HR+, HER2-, Advanced Breast Cancer, Early Hormone Receptor Positive, HER2/Neu Negative Node Positive Breast Cancer, Metastatic HR + HER2 - breast cancer
Associated Therapies
-
Clinical Trials
Related News

CAMPFIRE: A Study of Abemaciclib (LY2835219) in Participants With Ewing's Sarcoma

First Posted Date
2022-07-01
Last Posted Date
2024-12-11
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
45
Registration Number
NCT05440786
Locations
🇺🇸

Phoenix Children's Hospital, Phoenix, Arizona, United States

🇺🇸

The Regents of the University of California - Los Angeles (UCLA Pediatrics), Los Angeles, California, United States

🇺🇸

Riley Hospital for Children at Indiana University Health, Indianapolis, Indiana, United States

and more 24 locations

Study of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to ER+/HER-2- Breast Cancer

First Posted Date
2022-05-23
Last Posted Date
2024-11-21
Lead Sponsor
Stemline Therapeutics, Inc.
Target Recruit Count
68
Registration Number
NCT05386108
Locations
🇫🇷

Centre Léon Bérard - Département Oncologie Médicale, Lyon, France

🇩🇪

Universitätsklinikum Leipzig, Leipzig, Germany

🇺🇸

Providence Medical Foundation, Fullerton, California, United States

and more 70 locations

Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors

First Posted Date
2022-05-13
Last Posted Date
2024-10-09
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
30
Registration Number
NCT05372640
Locations
🇺🇸

Los Angeles General Medical Center, Los Angeles, California, United States

🇺🇸

USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States

🇺🇸

University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States

and more 4 locations

A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors

First Posted Date
2022-04-01
Last Posted Date
2024-10-26
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
400
Registration Number
NCT05307705
Locations
🇺🇸

Massachusetts General Hospital, Boston, Massachusetts, United States

🇺🇸

DFCI, Boston, Massachusetts, United States

🇺🇸

Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States

and more 52 locations

A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)

First Posted Date
2022-03-21
Last Posted Date
2024-07-18
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
900
Registration Number
NCT05288166
Locations
🇺🇸

AHN Allegheny General Hospital, Pittsburgh, Pennsylvania, United States

🇺🇸

UT Southwestern Medical Center, Dallas, Texas, United States

🇲🇽

Hospital Universitario "Dr. Jose Eleuterio Gonzalez", Monterrey, Nuevo León, Mexico

and more 260 locations

Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer

First Posted Date
2021-12-27
Last Posted Date
2024-12-09
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
368
Registration Number
NCT05169567
Locations
🇨🇳

Taipei Tzu Chi General Hospital, New Taipei City, Taiwan

🇩🇰

Regionshospitalet Gødstrup, Herning, Midtjylland, Denmark

🇭🇺

Bacs-Kiskun Megyei Korhaz, Kecskemét, Bács-Kiskun, Hungary

and more 130 locations

The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs

First Posted Date
2021-12-16
Last Posted Date
2024-07-15
Lead Sponsor
Helsinki University Central Hospital
Target Recruit Count
250
Registration Number
NCT05159245
Locations
🇫🇮

Turku University Hospital Cancer Centre, Turku, Varsinais-Suomi, Finland

🇫🇮

Kuopio University Hospital, Kuopio, Finland

🇫🇮

Oulu University Hospital OYS Cancer Center, Oulu, Finland

and more 2 locations

Description of Treatment Patterns and Description and Comparison of Healthcare Resource Utilization and Costs of Women With Metastatic HR+/HER2- Breast Cancer Treated With CDK4/6 Inhibitors

First Posted Date
2021-12-10
Last Posted Date
2021-12-21
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
4320
Registration Number
NCT05153135
Locations
🇺🇸

Novartis Investigative Site, East Hanover, New Jersey, United States

A Real-world Analysis of Concomitant Medication Use Among Metastatic Breast Cancer Patients Treated With CDK4/6 Inhibitors

First Posted Date
2021-12-02
Last Posted Date
2021-12-16
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
4650
Registration Number
NCT05141240
Locations
🇺🇸

Novartis Investigational site, East Hanover, New Jersey, United States

Abemaciclib Before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer

First Posted Date
2021-11-09
Last Posted Date
2024-05-29
Lead Sponsor
Vadim S Koshkin
Target Recruit Count
30
Registration Number
NCT05113537
Locations
🇺🇸

University of California, San Francisco, San Francisco, California, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy